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ABSTRACT
Objective: The objective of the work is to formulate chlorzoxazone floating bioadhesive tablets which will significantly improve the bioavailability of 
drugs under the condition of prolonged use of drugs and reduce the total dosage of administered drug and reduce the side effect.
Methods: Floating bioadhesive tablet was prepared by direct compression of polymer such as HPMCK4M and Carbopol934p in combination.
Result: After analysis of different evaluation parameter and drug release, F9 batch was selected as promising formulation for delivery of chlorzoxazone 
floating bioadhesive tablets with 92.1% drug release at 12th h.
Conclusion: It was observed that the combination of polymers in 22.5% (HPMCK4M) and 12.5% (Carbopol 934p) give the best drug release and 
sustain the drug release for 12 h. Among the other batches, F9 batch was selected as an optimized batch because the pre- and post-compression 
parameters results are satisfactory.
Keywords: Chlorzoxazone, Floating bioadhesive tablets, HPMCK4M, Carbopol 934p, Direct compression.
INTRODUCTION
The design of oral modified release dosage form is intended to optimize 
a therapeutic regimen by providing controlled delivery of drug over the 
entire dosing interval. Among the various routes of administration oral 
intake have long been the most convenient and commonly employed 
route. There are many ways to intend modified release dosage forms for 
oral administration and one of them is floating bioadhesive tablets [1].
FBDS is a gastro-retentive dosage form, which can prolong the gastric 
residence time to produce an acceptable drug bioavailability. Floating 
bioadhesive drug delivery system (FBDDS) is suitable for drugs with 
an absorption window in the stomach or the upper small intestine, for 
drugs which act locally in the stomach and for drugs that are poorly 
soluble or unstable in the intestinal fluid FBDDS or hydro-dynamically 
balanced systems have a bulk density lower than gastric fluid and thus 
remain buoyant in the stomach without affecting the gastric emptying 
rate for a prolonged period of time. Based on the mechanism of 
buoyancy, two distinctly different technologies, i.e., non-effervescent 
and effervescent systems, have been used in the development of 
FBDDS.
The effervescent system uses matrices prepared with swellable 
polymers and effervescent components, for example, sodium 
bicarbonate and citric acid or stearic acid. In non-effervescent FBDDS, 
the drug mixes with a gel-forming hydrocolloid, which swells in contact 
with gastric fluid after oral administration to maintain a relatively stable 
shape and a bulk density of less than unity within the outer gelatinous 
barrier. The air trapped by the swollen polymer confers buoyancy on 
these dosage forms [2].
Chlorzoxazone (structure shown in Fig. 1), (2-hydroxy-5-chlorobenzoxazole) 
is a Class-II drug low solubility, high permeability, a centrally acting central 
muscle relaxant with sedative properties. It is claimed to inhibit muscle 
spasm by exerting an effect primarily at the level of the spinal cord and 
subcortical areas of the brain [3].
MATERIALS AND METHODS
Chlorzoxazone was a procured from Yarochem, Mumbai. HPMCK4M were 
procured from Chemdyes Corporation, Gujarat. Carbopol 934p were 
procured from Research Lab-Fine Chem. Industries, Mumbai. Lactose, 
Sodium Bicarbonate, Magnesium stearate was procured from Thomas 
Baker Pvt. Ltd, Mumbai. All reagents used were of analytical grade.
METHODS
Drug excipient compatibility studies
Fourier-transform infrared (FT-IR) spectrum matching approach was 
used for detection of any possible chemical interaction between the 
chlorzoxazone and polymers. IR spectroscopy was conducted using 
a FTIR spectrophotometer (Jasco FT-IR 410), and the spectrum was 
recorded in the wavelength region of 4000–400/cm. The procedure 
consisted of dispersing a sample (drug alone or mixture of drug and 
excipients) in KBr and compressed into discs by applying a pressure 
of 5 tons for 5 min in a hydraulic press. The pellet was placed in the 
light path, and the spectrum was obtained. Samples were prepared for 
chlorzoxazone, polymers such as Carbopol 934, HPMCK4M and physical 
mixture of drug with polymers. The spectra obtained were compared 
and interpreted for the functional group peaks [4].
Preformulation studies
Ultraviolet (UV)-spectrum of drug chlorzoxazone
The solution of chlorzoxazone in 0.1N HCL screened in the range of 
200–400 nm.
Melting point
The melting point of the drug was determined using packing a capillary 
method.
Physical properties of drug powder
The drug chlorzoxazone undergoes through various tests to know its 
physical properties.
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Construction of calibration curve
The calibration curve for chlorzoxazone was determined in 0.1N HCl pH 
1.2 in UV spectrophotometer in Fig. 2.
The flow properties of granules were characterized in terms of angle 
of repose, Carr’s index, Compressibility index, and Hausner’s ratio. The 
bulk density and tapped density were determined, and from this data, 
Carr’s index and Hausner’s ratio were calculated [5].
Formulation of floating bioadhesive tablet of chlorzoxazone
Floating bioadhesive drug delivery of chlorzoxazone was prepared by 
direct compression method. The composition of formulations is shown 
in Table 1. All the powders were passed through a 60 mesh sieve. 
The required quantity of drug, polymers mixture and diluents were 
mixed. The powder blend was lubricated with magnesium stearate and 
compressed using (11.6 mm diameter punches) multiple punch rotary 
tablet machine. In total, 9 formulations containing different amounts of 
HPMCK4M and Carbopol934p combination were prepared.
Characterization of matrix tablets
Thickness
Selected randomly 5 tablets from each batch were used for thickness 
determination. The thickness of each tablet was measured in mm using 
a digital Vernier Caliper their values were reported in millimeters. The 
mean and standard deviation was calculated and reported.
Weight variation test
A total of 20 tablets were selected randomly from each batch and 
individually weighed using an electronic balance. The average weight 
was calculated. The percentage deviation from average weight was 
reported.
Hardness
The hardness of five tablets which randomly selected from each 
batch was measured using Monsanto hardness tester and expressed 
in kg/cm2.
Friability
Five tablets were randomly selected from each batch and accurately 
weigh the tablet sample, and place the tablets in the drum. Rotate the 
drum 100 times, and remove the tablet re-weighed and percentage 
loss was determined. Friability of tablets was performed using Roche 
Friabilator.
Drug content analysis
Five tablets were weighed individually, and the average was calculated 
and grounded in a mortar with a pestle to get a fine powder. An amount 
equivalent to 300 mg of the drug was extracted with 100 ml of 0.1 N 
HCl. The drug content was determined by UV spectrophotometer at a 
wavelength 282 nm, and the percentage drug content was calculated.
Swelling index
The swelling of the mucoadhesive polymer is an important factor 
affecting adhesion. To carry out the study, a tablet was weighed and 
placed in a Petri dish containing 5 ml of 0.1N HCL buffer pH 1.2 in 5 hrs 
at regular interval of time (1, 2, 3, 4, and 5) the tablet was taken care by 
using filter paper. The swelling index was calculated using the following 
formula,
Swelling index = wt−w0/w0×100
Mucoadhesive strength measurement [6-9]
The mucoadhesive strength of the tablet was measured on the modified 
physical balance apparatus consists of a modified double beam physical 
balance in which the right and left pan has been replaced by lighter 
pans. The left side of the balance was made 5 g heavier than the right 
side by placing a 5 g weight on left side pan. Another Teflon block of 3.8 
cm diameter and 2 cm height was fabricated with an upward portion of 
2 cm height and 1.5 cm diameter on one side. This was kept in a beaker, 
which was then placed below the left-hand set of the balance.
The goat gastric mucosa was used as the model membrane, and pH 1.2 
was used as the moistening fluid. The goat gastric mucosa was kept 
in Tyrode solution at 37°C for 2 h. The underlying mucous membrane 
was separated and washed thoroughly with a pH 1.2 solutions. It was 
then tied to a Teflon-coated glass slide, and this slide was fixed over 
the protrusion in the Teflon block using a thread. The block was then 
kept in a beaker containing pH 1.2 buffer solutions at the level that just 
touches the membrane. By keeping a 5 g weight on the right pan, the 
two sides of the balance were made equal. The beaker with the Teflon 
block was kept below the left hand set up of the balances. The tablets 
of each batch were struck on to the lower side of the left-hand side pan. 
The 5 g weight from the right pan was then removed. This lowered the 
left pan along with the tablet over the membrane with a weight of 5 g. 
This was kept undisturbed for 5 min. Then, the weight on the right-
hand side was slowly added in an increment of 0.5 g till the tablet just 
separated from the membrane surface. The excess weight on the right 
pan, i.e., total weight −5 g was taken as a measure of the mucoadhesive 
strength.
Table 1: Composition floating bioadhesive tablet of chlorzoxazone prepared by direct compression
Ingredient F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) F6 (mg) F7 (mg) F8 (mg) F9 (mg)
Chlorzoxazone 300 300 300 300 300 300 300 300 300
HPMC K4M 87.5 87.5 87.5 100 100 100 112.5 112.5 112.5
Carbopol 934p 20 25 30 20 25 30 20 25 30
Sodium bicarbonate 50 50 50 50 50 50 50 50 50
Mg. St. 5 5 5 5 5 5 5 5 5
Lactose 37.5 32.5 27.5 25 20 15 12.5 7.5 2.5
Total 500 500 500 500 500 500 500 500 500
Fig. 1: Chlorzoxazone drug structure
Fig. 2: Calibration curve of chlorzoxazone
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From the mucoadhesive strength, the force of adhesion was calculated 
using the following formula:
Force of  adhesion N  = Bioadhesive strength
100
× 9.81( )
In vitro buoyancy study [10]
The in vitro buoyancy was determined by measuring floating lag time 
and duration of buoyancy. The tablets were placed in a 100 ml beaker 
containing 100 ml of 0.1 N HCl. The time required for the tablet to rise 
to the surface and float was taken at the floating lag time. The time 
for which tablets kept floating was termed as “buoyancy time” of the 
tablets which were determined for all the formulations.
In vitro drug release study
In vitro, drug release studies were performed using the USP dissolution 
apparatus Type-II. The drug release profile was studied in 900 ml of 
0.1N HCl buffer of pH 1.2 at 37±0.2°C. The rotational speed of the paddle 
was 50 RPM. Aliquots of 5 ml of dissolution medium were withdrawn 
at specific time intervals, filtered and replaced with fresh medium. The 
samples were filtered through Whatman filter paper and analyzed after 
appropriate dilution by a UV spectrophotometer (Shimadzu UV 1800) 
at 282 NM, and drug release was determined from the standard curve.
Statistical analysis
To evaluate the contribution of each factor with different levels on 
responses, two-way analysis of variance (ANOVA) was performed using 
GraphPad Prism 7.04 Software.
RESULTS AND DISCUSSION
Drug excipient compatibility studies
The results showed that the principle IR peak of pure drug, its physical 
mixture with polymer was almost similar, signifying no interaction 
between drug and polymer during formulation of tablets.
UV-spectrum of drug chlorzoxazone
The solution of chlorzoxazone in 0.1N HCL was found to exhibit 
maximum absorption (λmax) at 282 nm after scanning in the range of 
200–400 nm. As shown in Fig. 3.
Physical properties of drug powder
The drug chlorzoxazone undergoes through various tests to know its 
physical properties Table 2.
Preformulation studies of powders
The prepared powders were characterized for angle of repose, 
bulk density, tapped density, Hausner’s factor, Carr’s index, and 
compressibility index and the values were reported in Table 3. The 
angle of repose of the different batches of powders was determined 
as per the method mentioned earlier, and the results ranged between 
20.005° and 24.38°. The powder with the angle of repose <20° indicates 
excellent flow properties. The bulk densities of powder were ranged 
between 0.25 g/cm3 and 0.33 g/cm3. The low bulk density is due to the 
presence of more fines in the powder. Tapped density ranged between 
0.303 g/cm3 and 0.4 g/cm3.
Evaluation of bioadhesive floating tablet
Weight variation, thickness, hardness, friability, and drug content 
analysis
The results were represented in Table 4. The diameters of prepared 
tablets were ranged from 11.98 to 12.003. The weights of prepared 
tablets were ranging from 488.1±24.40 to 494.2±24.71. The thickness 
of prepared tablets ranged from 4.08 to 4.48. It was also observed that 
increasing the polymer concentration resulted in a slight decrease in 
the thickness of tablet formulations. These results indicate that the 
polymers may have high binding properties. Hardness of tablet ranged 
from 5.16 to 7.34 kg/cm2. For all formulation, friability ranged from 
0.0 to 0.7% it indicating that friability is within the prescribed limit 
of 1%. The drug content (%) of floating bioadhesive tablet from each 
formulation was found to be uniform and ranged from 93.99 to 96.98%.
Swelling studies
Swelling index profile of all formulations is shown in Table 5 and 
Fig. 4. Swelling index of all formulations is varies between 230.61 and 
288.36%. Swelling of the matrix, this is indicated by the transition of 
the polymer from the glassy to the rubbery state. It is an important 
parameter in determining the release characteristics of the matrix 
system. As swelling process proceeds, the gel layer gradually becomes 
thicker, and therefore the drug concentration gradient along the 
diffusional path length is decreased results in the slow drug release.
Fig. 3: Ultraviolet spectrum of chlorzoxazone
Fig. 5: Bioadhesive strength of a tablet
Fig. 4: Swelling index studies of floating bioadhesive tablets
Table 2: Physical properties of drug powder
Sr. No Test Result
1 Bulk density (g/ml) 0.433
2 Tap density (g/ml) 0.534
3 Carr’s compressibility 19%
4 Hausner’s ratio 1.23
5 Angle of repose 30˚
Flow properties Passable
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Measurement of bioadhesion force
The mucoadhesive strength of the tablet was dependent on the property 
of the bioadhesive polymers, which on hydration adhere to the mucosal 
surface and also on the concentration of polymer used. Bioadhesive 
force values ranged from 2.94 to 4.91. Results were represented in 
Table 6 and Fig. 5.
In vitro buoyancy study
Floating lag time of all nine batches shown in Table 7.
In vitro dissolution studies
All the nine formulations were subjected to in vitro dissolution studies 
using a USP Type-II dissolution test apparatus. The dissolution medium 
Table 3: Pre-compression parameter of blend












F1 0.33 0.4 16.66 1.21 18 20.005
F2 0.303 0.384 21.21 1.267 22 23.85
F3 0.277 0.344 19.44 1.515 20 21.55
F4 0.294 0.344 14.70 1.12 14.6 21.31
F5 0.25 0.33 25 1.32 25 21.75
F6 0.25 0.312 20 1.248 19.9 21.44
F7 0.25 0.303 17.5 1.212 17.5 22.04
F8 0.263 0.303 13.5 1.152 13.3 24.38
F9 0.277 0.33 16.66 1.19 17 21.75









Friability (%) % Weight  
variation^
% drug  
content*
F1 11.98±0.005 4.18±0.036 5.16±0.288 0 492.4±24.62 93.99±0.00
F2 11.99±0.005 4.08±0.011 5.33±0.288 0.7 493.5±24.67 94.86±0.375
F3 11.99±0.005 4.32±0.034 5.5±0.00 0.5 491.8±24.59 96.56±0.640
F4 12.003±0.005 4.40±0.02 6±0.00 0.6 493.9±24.69 96.56±0.640
F5 12.003±0.005 4.48±0.011 6.16±0.288 0 493.2±24.66 95.07±0.375
F6 12±0.017 4.48±0.015 6.16±0.288 0.6 489.6±24.48 95.93±0.00
F7 11.99±0.005 4.33±0.02 7±0.00 0.5 493.6±24.68 96.76±0.393
F8 11.98±0.01 4.3±0.026 7.16±0.288 0.7 488.1±24.40 96.77±0.416
F9 11.99±0.02 4.32±0.01 7.34±0.288 0 494.2±24.71 96.98±0.393
*All values expressed in mean±SD, n=3, ^all value expressed in mean±SD, n=10. SD: Standard deviation
Table 5: Swelling index studies of floating bioadhesive tablets
Time %F1 %F2 %F3 %F4 %F5 %F6 %F7 %F8 %F9
0 0 0 0 0 0 0 0 0 0
1 61.22 53.60 43.15 37.37 44.92 35.41 25.25 32.65 22.91
2 83.67 89.69 70.12 100.00 102.89 83.33 75.75 69.38 56.25
3 157.14 143.29 148.96 126.26 156.72 120.83 140.40 110.20 106.25
4 196.93 206.59 173.85 180.80 229.19 197.91 172.72 161.22 166.67
5 288.36 283.50 263.07 261.61 266.45 264.58 243.43 230.61 231.25
Fig. 6: In vitro drug release profile of batches (F1-F3)
Table 6: Bioadhesive strength of a tablet










Table 7: Floating lag time
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1.2 pH buffer was used to study the drug release. The samples were 
withdrawn at different intervals of time and analyzed at 282 NM using 
a UV spectrophotometer. The cumulative percentage drug release was 
calculated. The data obtained from in vitro release for formulations 
prepared by direct compression technique are tabulated in Table 8.
In vitro dissolution studies of nine batches that the batch F1, F2, and F3 
tablets completely disintegrated at 8 h (Fig. 6) and batch F4, F5, and F6 
completely disintegrated at 10 h, so these batches were rejected (Fig. 7). 
Among the other batches, F7, F8, and F9 batches were completely 
disintegrated at 12 h (Fig. 8).
CONCLUSION
Floating mucoadhesive tablet of chlorzoxazone was prepared by direct 
compression method using a polymer such as HPMC K4M, Carbopol 
934p, and other excipients. All pre- and post-compression study was 
done in all nine batches of the tablet. In vitro dissolution studies of nine 
batches concluded that the batch F1, F2, and F3 tablets completely 
Fig. 7: In vitro drug release profile of batches (F4-F6)
Table 8: In vitro dissolution study of tablets
Time (h) F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0±0 0±0 0±0 0±0 0±0 0±0 0±0 0±0 0±0
1 25.33±0.05 22.52±0.01 16.61±0.17 15.57±0.27 8.32±0.10 6.66±0.32 6.63±0.29 6.6±0.27 3.86±0.14
2 32.72±0.15 30.07±0.09 27.10±0.04 21.33±0.21 21.32±0.21 18.36±0.21 16.55±0.40 14.26±0.26 9.48±0.31
3 53.14±0.15 50.03±0.23 43.23±0.29 47.32±0.22 32.66±0.18 35.61±0.09 29.69±0.24 35.6±0.08 24.42±0.22
4 70.70±0.17 57.52±0.36 59.31±0.40 57.47±0.33 55.98±0.16 53.35±0.38 50.38±0.36 41.51±0.35 37.38±0.36
6 80.48±0.23 79.76±0.55 70.21±0.23 73.15±0.15 67.20±0.23 64.24±0.24 58.32±0.42 58.31±0.41 55.32±0.42
8 98.21±0.04 92.62±0.42 85.16±0.06 83.37±0.29 73.65±0.47 73.75±0.35 74.51±0.34 71.54±0.40 67.4±0.20
10 - - - 88.51±0.12 83.18±0.45 82.52±0.11 82.41±0.26 78.38±0.29 83.57±0.11
12 - - - - - - 87.41±0.26 88.53±0.12 92.1±0.77
Fig 8: In vitro drug release profile of batches (F7-F9)
disintegrated at 8 h and batch F4, F5, and F6 completely disintegrated 
at 10 h, so these batches were rejected. Among the other batches, F9 
batch was selected as an optimized batch because the pre- and post-
compression parameters results are satisfactory. The F9 batch showed 
that the best result as the percent cumulative drug release of F9 is 
91.22% at 12 h.
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